Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Non Operating Income (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Non Operating Income data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Non Operating Income rose 278.11% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $4.7 million, up 130.61%, while the annual FY2024 figure was $2.1 million, 17.17% up from the prior year.
  • Non Operating Income reached $1.7 million in Q3 2025 per CAPR's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.8 million in Q2 2025 and bottomed at $9165.0 in Q1 2021.
  • Average Non Operating Income over 5 years is $504991.4, with a median of $416442.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: surged 9582.22% in 2021, then crashed 72.14% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $189118.0 in 2021, then surged by 82.65% to $345433.0 in 2022, then skyrocketed by 50.3% to $519203.0 in 2023, then rose by 11.95% to $581238.0 in 2024, then soared by 194.78% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $1.7 million in Q3 2025, $1.8 million in Q2 2025, and $591354.0 in Q1 2025.